Robert H. Jones

Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours

Robert H. Jones, David James Pinato, Martin D. Forster, Anthony M. Joshua et autres

gb, au (code pays fourni par la source)

Demographic and Disease Characteristics from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Robert H. Jones, Ruth Plummer, Víctor Moreno, Louise Carter et autres

Patients are displayed in cohorts defined by tumor type, including indication-specific expansion cohorts (anogenital, cervical, HGSOC, SCLC and STS), a grouping of patients with rectal cancer who were enrolled under dose escalation, and four patients with urothelial cancer enrolled under previous protocol …

Mean exposure (AUC0–12) by dose level from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Robert H. Jones, Ruth Plummer, Víctor Moreno, Louise Carter et autres

This figure displays the mean area under the SRA737 plasma concentration-time curve from 0 to 12 hours (AUC0–12) following a single oral dose of SRA737 at doses of 150, 300, 500 and 600 mg. Error bars represent standard deviation.

Mean plasma SRA737 concentration over time from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Robert H. Jones, Ruth Plummer, Víctor Moreno, Louise Carter et autres

This figure displays the mean SRA737 plasma concentration at each assessment timepoint by dose level. The dotted lines indicates a plasma concentration of 40-500 ng/mL, the range corresponding to the minimal effective dose extrapolated from preclinical models. Error bars represent standard deviation.

Supplementary Methods. MS1 from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Robert H. Jones, Ruth Plummer, Víctor Moreno, Louise Carter et autres

Study inclusion and exclusion criteria.

Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology

Richard Phillips, Bristi Basu, Zohra Butt, Mounia Beloueche et autres

BACKGROUND: The Experimental Cancer Medicine Centre (ECMC) Network supports UK-wide access to experimental cancer therapies, many of which require specific genomic alterations. This study aimed to develop expert consensus on essential genes for a pan-cancer sequencing panel, involving subject matter experts (SMEs) …

gb, de (code pays fourni par la source)

948P Cancer Research UK first-in-human (FIH) phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 (HTL) as monotherapy and in combination with immunotherapy in patients with advanced solid tumours

Bristi Basu, Noah R. Cook, Robert H. Jones, Daniel H. Palmer et autres

pt, gb, au, ca (code pays fourni par la source)

Abstract P1-01-19: Predicting response to capivasertib in AKT1 mutant advanced breast cancer

Sarah Mearns, Alexander T. Pearson, Ros Cutts, Heena Pradeep Shah et autres

Abstract Introduction: Activation of the PI3K-AKT and mTOR pathways is a major feature of the biology of breast cancer (BC), with these pathways altered or dysregulated in most BC. Oncogenic mutations in AKT1, most frequently E17K, are found in ∼5% of advanced …

Abstract CT176: Pharmacokinetics (PK) of the novel nonsteroidal CYP11A1 inhibitor opevesostat (ODM-208/MK-5684): Interaction potential with midazolam and effect of food

Natalie Cook, Jan de Hoon, Arif Hussain, Robert H. Jones et autres

Abstract Background: Opevesostat is an oral, nonsteroidal small molecule that selectively inhibits the mitochondrial cholesterol side-chain cleavage enzyme cytochrome P450 11A1 (CYP11A1). In vitro, the active metabolite M1 of opevesostat showed a time-dependent inhibition of CYP3A4. It is crucial to investigate factors …

gb, be, us, fr, fi (code pays fourni par la source)

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer

Karam Aboud, Magdalena Meissner, Robert H. Jones

The landscape of breast cancer treatment continues to evolve. Survival rates have improved due to advancements in treatments such as endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and targeted therapies. The PI3K/AKT/PTEN signalling pathway, frequently mutated in breast cancer, is a key target. …

gb (code pays fourni par la source)

Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial

Heinz‐Josef Lenz, Tianshu Liu, Emerson Y. Chen, Zsolt Horváth et autres

BACKGROUND: In metastatic colorectal cancer (mCRC), improvements in survival from combining leucovorin/fluorouracil/oxaliplatin/irinotecan (FOLFOXIRI) with bevacizumab have come at the risk of increased rates of high-grade toxicities. Trilaciclib is indicated to decrease the incidence of chemotherapy-induced myelosuppression in patients receiving standard-of-care chemotherapy for …

us, cn, hu, ua, it, es, gb, ch (code pays fourni par la source)

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment

Antonino Glaviano, Seth Andrew Wander, Richard D. Baird, Kenneth Chun-Yong Yap et autres

Cell cycle dysregulation is a hallmark of cancer that promotes eccessive cell division. Cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) are key molecules in the G1-to-S phase cell cycle transition and are crucial for the onset, survival, and progression of …

it, us, gb, sg, jp, fr, es (code pays fourni par la source)